FDA Safety and Innovation Act, Part 1
Senior Food and Drug Administration (FDA) officials gave an update on the implementation of the 2012 FDA Safety and Inno…
Mentions rare disease, accelerated approval, Duchenne muscular dystrophy; Sarepta Therapeutics & eteplirsen, patient advocacy, establishing natural history of rare diseases
Senior Food and Drug Administration (FDA) officials gave an update on the implementation of the 2012 FDA Safety and Inno…
Physicians and medical researchers talked about ways for the Food and Drug Administration to correct misinformation in t…
A forum on transparency at the Food and Drug Administration featured a discussion on how transparency can affect investo…
Witnesses testified at a hearing on the Food and Drug Administration’s FDA’s proposal to have generic drug makers update…